Breaking News Instant updates and real-time market news.

QCOM

Qualcomm

$81.97

2.08 (2.60%)

, TWTR

Twitter

$34.39

-0.01 (-0.03%)

07:35
04/23/19
04/23
07:35
04/23/19
07:35

Unusual call flow in option market yesterday

Notable call activity was cited Monday in Qualcomm (QCOM), Twitter (TWTR), Ford (F), Canopy Growth (CGC), Teva (TEVA), General Motors (GM), Blackstone (BX), D R Horton (DHI), Sirius XM (SIRI), and Box (BOX).

QCOM

Qualcomm

$81.97

2.08 (2.60%)

TWTR

Twitter

$34.39

-0.01 (-0.03%)

F

Ford

$9.34

-0.06 (-0.64%)

CGC

Canopy Growth

$48.22

3.79 (8.53%)

TEVA

Teva

$14.70

0.34 (2.37%)

GM

General Motors

$39.50

-0.8 (-1.99%)

BX

Blackstone

$39.04

0.39 (1.01%)

DHI

D.R. Horton

$45.66

-0.76 (-1.64%)

SIRI

Sirius XM

$6.11

0.07 (1.16%)

BOX

Box

$19.71

0.86 (4.56%)

  • 23

    Apr

  • 24

    Apr

  • 25

    Apr

  • 25

    Apr

  • 30

    Apr

  • 01

    May

  • 02

    May

  • 03

    May

  • 03

    May

  • 04

    May

  • 09

    May

  • 20

    May

  • 23

    May

  • 05

    Jun

  • 05

    Jun

  • 11

    Jun

  • 23

    Oct

QCOM Qualcomm
$81.97

2.08 (2.60%)

04/18/19
ARGS
04/18/19
NO CHANGE
Target $225
ARGS
Buy
Apple to benefit from Qualcomm litigation settlement, says Argus
Argus analyst Jim Kelleher kept his Buy rating and $225 price target on Apple (AAPL), saying the company's "comprehensive legal settlement and new supply agreement with Qualcomm (QCOM)" should benefit the shares. The analyst notes that the decision to settle was driven by the realization that Apple may miss out on the 5G phone cycle upgrade, and the announcement by Intel (INTC) within hours of the settlement highlighted that the Street was more optimistic about its development of a viable 5G chip. Kelleher adds that the cost burden for Qualcomm chip and licensing is not "too severe", which he estimates to be below $25 on devices that may retail for over $1.1K. The analyst also notes that Apple stock remains "attractive compared to its historical valuations and to peer average multiples."
04/23/19
MSCO
04/23/19
UPGRADE
Target $95
MSCO
Overweight
Morgan Stanley upgrades Qualcomm, thinks Apple pact not yet fully appreciated
As previously reported, Morgan Stanley analyst James Faucette upgraded Qualcomm (QCOM) to Overweight from Equal Weight, citing his view that the market has "not yet fully appreciated" the impact of the company's settlement with Apple (AAPL), which he thinks not only increases earnings substantially while also expanding the freedom with which Qualcomm can pursue new opportunities. Faucette thinks the settlement reinforces two key Qualcomm tenets - the best modem performance matters and that the best intellectual property has value. While he takes a more conservative view than most on the pace of 5G ramp, Faucette said he views Qualcomm as "the key enabler" of 5G technology. He raised his price target on Qualcomm shares to $95 from $55.
04/23/19
MSCO
04/23/19
UPGRADE
MSCO
Overweight
Qualcomm upgraded to Overweight from Equal Weight at Morgan Stanley
04/18/19
04/18/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. PepsiCo (PEP) upgraded to Neutral from Sell at Goldman Sachs with analyst Judy Hong citing its "strong" Q1 results that saw organic revenue accelerate to 5% and gross margins top expectations. 2. J.M. Smucker (SJM) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst Pamela Kaufman saying she believes the company's reinvestment strategy will drive improved topline momentum across its key segments and should allow the company to return to positive organic growth in FY20. 3. Venator Materials (VNTR) upgraded to Outperform from Sector Perform at RBC Capital with analyst Arun Viswanathan saying he believes that the titanium dioxide "cycle is turning", with destocking activity nearing completion amid improving global demand and pricing. 4. Ecolab (ECL) upgraded to Buy from Neutral at Nomura Instinet with analyst Dan Dolev saying with the problematic energy business soon to be spun-off, Ecolab's "recession resistant qualities should stand out, warranting a significant premium to peers." 5. Qualcomm (QCOM) upgraded to Buy from Hold at DZ Bank. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
TWTR Twitter
$34.39

-0.01 (-0.03%)

04/22/19
CLVD
04/22/19
NO CHANGE
CLVD
Neutral
Twitter ad spending remains 'encouraging,' says Cleveland Research
Cleveland Research analyst Chandler Converse says his firm's research suggests that advertising spending on Twitter remains "encouraging." The analyst sees "strong" ad engagements and like-for-like growth after budgets, according to his firm's work, finished in-line with consensus expectations and at the high-end of Twitter's Q1 guidance. He continues to expect above-consensus advertising revenue for Twitter in 2019 on "strong execution with partners." Converse has a Neutral rating on the shares.
04/22/19
JEFF
04/22/19
NO CHANGE
JEFF
Jefferies still prefers Facebook in social, calls Twitter 'reasonably valued'
Social stocks have outperformed year-to-date, up ~55% versus the Nasdaq's rally of 20%, with Snap (SNAP) being the top performer up 120% after lagging the group in 2018, Jefferies analyst Brent Thill tells investors in a research note. The analyst continues to prefer share of Facebook (FB) in social with a Buy rating and $200 price target. He sees upside in average revenue per user and operating expenditure growth. Meanwhile, Thill is "incrementally positive" on Snap's "encouraging momentum," but says the company is "not out of the woods yet." If Snap can deliver on daily active user growth in Q1 it should be a catalyst for shares, however with the stock trading at nine-times 2019, these improvements are largely priced in, Thill tells investors in a pre-earnings research note. And while the analyst remains "fundamental fans" of Twitter, he views the stock as "reasonably valued." Further, Twitter faces tough comps for international in the first half of 2019 and for the U.S. in the second half of the year, Thill points out.
04/18/19
WEDB
04/18/19
NO CHANGE
Target $37
WEDB
Neutral
Twitter Q1 results expected at high end of guidance range, says Wedbush
Wedbush analyst Michael Pachter expects Twitter to report Q1 results at the high end of the guidance range, with no meaningful change to outlook. Twitter appears to be making progress toward sustainable revenue growth and margin expansion, he acknowledges. But given uncertainty over user growth, relatively "unimpressive" mDAU levels, and relatively rich valuation, Pachter reiterates a Neutral rating and a $37 price target on the shares.
04/22/19
BARD
04/22/19
NO CHANGE
Target $33
BARD
Neutral
Twitter to meet or beat Q1 revenue estimates, says Baird
Baird analyst Colin Sebastian expects Twitter tomorrow morning to meet or beat Q1 revenue expectations "given what appeared to be conservative guidance." Further, digital marketing trends in the quarter were stable, Sebastian tells investors in a pre-earnings research note. The analyst thinks Twitter will report Q1 revenue in line or above the high end of management's guidance range, driven by "healthy" monthly daily active user trends of up 9% year-over-year. Sebastian keeps a Neutral rating on the shares with a $33 price target.
F Ford
$9.34

-0.06 (-0.64%)

04/23/19
PIPR
04/23/19
NO CHANGE
PIPR
Piper sees U.S. ride-hailing market reaching $500B per year by 2040
Piper Jaffray expects the U.S. ride-hailing market will achieve annual revenue of $500B per year by 2040, analysts led by Alexander Potter tell investors in a research note. The firm, which utilized baseline data from the National Household Travel Survey, expects ride-hailing growth to continue, with around one-third of urban trips relying on shared third-party vehicles in 2040. This compares to a baseline of only 1.4% in 2017, and equates to a 20-year annual growth rate of ~14%, the analysts contend. Of the stocks with exposure to this trend, Piper prefers Lyft (LYFT), General Motors (GM) and NXP Semiconductors (NXPI). Other covered companies also warrant mention, including Apple (AAPL), Amazon.com (AMZN), Aptiv (APTV), Ford (F), Nvidia (NVDA), and Tesla (TSLA), says Piper.
04/05/19
NOMU
04/05/19
DOWNGRADE
Target $7.5
NOMU
Reduce
Ford downgraded to Reduce on Europe challenges at Nomura Instinet
Nomura Instinet analyst Anindya Das downgraded Ford to Reduce from Neutral after lowering his volume forecast for Europe in March and revising his estimates for the extent of electrification required to meet the EU's upcoming emissions standards. Ford's higher share of the U.K. auto market compared to the rest of Europe makes it more susceptible to Brexit risks, Das added. He cut his price target on Ford shares to $7.50 from $8.20.
04/05/19
NOMU
04/05/19
DOWNGRADE
NOMU
Reduce
Ford downgraded to Reduce from Neutral at Nomura Instinet
04/05/19
04/05/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Intel (INTC) downgraded to Market Perform from Outperform at Wells Fargo with analyst Aaron Rakers saying the shares, after rallying 19% year-to-date, reflect a more balanced risk/reward. 2. Boston Beer (SAM) downgraded to Sell from Neutral at Goldman Sachs with analyst Judy Hong saying she sees headwinds in 2019 as competition intensifies and the company is "unlikely to repeat its innovation success again this year." 3. Ford (F) downgraded to Reduce from Neutral at Nomura Instinet with analyst Anindya Das saying Ford's higher share of the U.K. auto market compared to the rest of Europe makes it more susceptible to Brexit risks. 4. Constellation Brands (STZ) downgraded to Hold from Buy at Deutsche Bank. 5. International Paper (IP) downgraded to Sector Perform from Outperform at RBC Capital with analyst Paul Quinn saying while International Paper is a "great company," investors have increased scrutiny on the containerboard market due to the "softening demand and fears of incremental capacity coming online" as year-to-date shipment growth slowed to 0.8% from 1.5% in 2018. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
CGC Canopy Growth
$48.22

3.79 (8.53%)

04/22/19
BNCH
04/22/19
NO CHANGE
BNCH
Buy
Canopy Growth acquisition provides path to U.S. market, says Benchmark
The acquisition of Acreage Holdings provides a path for Canopy Growth to enter the U.S. market upon eventual federal legalization of cannabis production and sale, Benchmark analyst Mike Hickey tells investors in a research note. The analyst estimates the U.S. cannabis market is 10 times the Canadian market. He keeps a Buy rating on Canopy Growth shares with a C$100 price target. However, cannabis sales data from Canada Health suggests a slow start to Q1, Hickey points out. As such, he expects the company to report fiscal Q4 sales of C$93M, below the consensus of C$98M. Canopy Growth in early trading is up 2% to $45.52 after GMP Securities upgraded the shares to Buy.
04/22/19
JEFF
04/22/19
NO CHANGE
Target $275
JEFF
Buy
Constellation Brands price target raised to $275 from $267 at Jefferies
Jefferies analyst Kevin Grundy raised his price target for Constellation Brands (STZ) to $275 from $267 to reflect the amended Canopy Growth (CGC) warrants held by the company, which was announced with Canopy's proposed acquisition of Acerage. Constellation agreed to waive its veto rights on the deal, subject to "favorably" modified warrant terms, which enhances the company's value in return for potential dilution from the deal and provides capital flexibility, Grundy tells investors in a research note. Constellation remains his top pick with a Buy rating.
04/22/19
MITR
04/22/19
UPGRADE
MITR
Buy
Canopy Growth upgraded to Buy after Acreage deal at GMP Securities
As previously reported, GMP Securities analyst Martin Landry upgraded Canopy Growth (CGC) to Buy from Hold after the company confirmed a deal giving it the right to acquire Acreage Holdings (ACRGF) upon cannabis production and sale becoming federally legal in the U.S., giving Canopy exposure to the largest cannabis market in the world. He sees significant near-term synergies and believes "the price is right," arguing that the takeout multiple is low given the strategic nature of the acquisition and Acreage's potential for continued strong growth. Landry raised his price target on Canopy shares to C$72 from C$65.
04/22/19
MITR
04/22/19
UPGRADE
MITR
Buy
Canopy Growth upgraded to Buy from Hold at GMP Securities
TEVA Teva
$14.70

0.34 (2.37%)

04/16/19
CANT
04/16/19
NO CHANGE
Target $58
CANT
Overweight
Eagle agreement with Teva could be worth $5 per share, says Cantor Fitzgerald
Eagle Pharmaceuticals (EGRX) announced yesterday that it renegotiated its revenue arrangement with Teva (TEVA), whereby the royalty rate on Bendeka sales would increase to 30% from 25% on October 1, 2019, and increase by 1% a year until the rate reaches 32%, Cantor Fitzgerald analyst Brandon Folkes tells investors in a research note. The analyst views the announcement as a positive for Eagle shares. Based on his current Bendeka assumptions, he believes the announcement could be worth up to $5 per share. With Eagle Pharmaceuticals shares up 1.8% yesterday, the market appears to have overly discounted the potential upside from the news, says Folkes. He keeps an Overweight rating on the name with a $58 price target.
03/28/19
03/28/19
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Lyft (LYFT) initiated with a Neutral at Wedbush. 2. The Medicines Co. (MDCO) initiated with an Outperform at Baird. 3. Fate Therapeutics (FATE) initiated with an Outperform at SVB Leerink. 4. Teva (TEVA) initiated with a Market Perform at BMO Capital. 5. Pebblebrook Hotel (PEB) initiated with a Neutral at Citi. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/22/19
CANT
04/22/19
NO CHANGE
Target $75
CANT
Overweight
Emergent shares largely pricing in Teva approval, says Cantor Fitzgerald
The FDA on Friday granted Teva Pharmaceutical (TEVA) final approval for its generic version of Narcan, Cantor Fitzgerald analyst Brandon Folkes tells investors in a research note. The analyst views the announcement as largely anticipated following the expiration of Teva's 30- month stay last month. Shares of Emergent BioSolutions (EBS) are down 18.7% since reporting Q4 earnings, largely driven by the anticipation of a final approval of Teva's generic naloxone, says Folkes. While Friday's approval is a negative and will continue to create an overhang on Emergent shares, the recent weakness has "adequately accounted for this overhang," he contends. As such, Folkes keeps an Overweight rating on Emergent BioSolutions with a $75 price target.
04/18/19
PIPR
04/18/19
NO CHANGE
PIPR
Teva gains ground on Amgen in latest migraine survey, says Piper Jaffray
Following of survey of 99 neurologists done by his firm's partner Spherix Global Insights, Piper Jaffray analyst Christopher Raymond maintains an Overweight rating on Amgen (AMGN) and a Neutral rating on Teva Pharmaceutical (TEVA). The migraine survey indicates Eli Lilly's (LLY) Emgality is lagging and that Teva's Ajovy appears to be gaining ground on Amgen's Aimovig across numerous metrics, Raymond tells investors in a research note. While one data point does not a trend make, this move warrants close attention, especially given the increased significance assigned to Aimovig with respect to Amgen sentiment, says the analyst. Raymond, however, remains cautious on Teva shares given the" lack of clarity regarding when/where EBITDA will hit a trough." On the R&D side, the analyst notes that Overweight-rated Alder Biopharmaceuticals' (ALDR) eptinezumab "appears to be particularly top-of-mind among migraine specialists."
GM General Motors
$39.50

-0.8 (-1.99%)

03/26/19
MSCO
03/26/19
NO CHANGE
Target $44
MSCO
Overweight
Morgan Stanley urges investors to lower expectations for GM Cruise unit
Morgan Stanley analyst Adam Jonas noted that GM's Cruise unit has stated a target to launch its robotaxi service by the end of 2019, but his view is that the technology required to remove human drivers at an acceptable level of safety is likely many years away. While "taking nothing away from GM Cruise," which Jonas thinks has important technological value, he urged investors to lower expectations for the unit's revenue generation and profitability. He said that if GM were to potentially recast its projected time horizon for the launch of its Cruise robotaxi service that he believes "the stock market would be largely understanding." Jonas keeps an Overweight rating and $44 price target on General Motors shares.
04/03/19
BMOC
04/03/19
NO CHANGE
BMOC
March U.S. auto sales mix negative for Magna, says BMO Capital
BMO Capital analyst Peter Sklar noted that Ward's Automotive reports that the U.S. light vehicle seasonally adjusted annual rate for March was 17.5M units, topping the consensus estimate of 16.8M vehicles. Sklar also pointed out that 12 of Magna's (MGA) top 20 North American programs underperformed the industry's selling rate of 1.5%. Publicly traded automakers include Daimler AG (DDAIF), Fiat Chrysler (FCAU), Ford (F), General Motors (GM), Honda (HMC), Nissan (NSANY), Symbol now VWAGY (VLKAY) and Toyota (TM).
03/13/19
MSCO
03/13/19
NO CHANGE
MSCO
Overweight
Morgan Stanley would be less surprised by GM's Cruise scaling back than growing
Following a recent Reuters report that said General Motors' (GM) Cruise unit plans to add 1,000 team members to double its headcount by year-end, Morgan Stanley analyst Adam Jonas said he would have been less surprised if Cruise was scaling back its growth plans rather than accelerating them given what he sees as "a general stalling" of autonomous vehicle expectations. His understanding is that the technology required to remove human drivers at an acceptable level of safety is likely many years away, said Jonas, who added that "it really matters" what Amazon (AMZN) is doing and whether it becomes a potential partner with GM, a competitor, or both. He maintains an Overweight rating on GM shares.
BX Blackstone
$39.04

0.39 (1.01%)

04/22/19
MSCO
04/22/19
NO CHANGE
Target $45
MSCO
Overweight
Blackstone price target raised to $45 from $40 at Morgan Stanley
Morgan Stanley analyst Michael Cyprys raised his valuation multiple on "sticky" management fee earnings at Blackstone and increased his price target on the stock to $45 from $40 following the company's announcement of plans to convert to a C-Corporation, stating that he believes the change from a partnership should unlock value by expanding the investor base that can participate. He believes multiple expansion should more than offset the expected 2%-5% hit to EPS over the next few years and 12%-13% longer-term hit from shifting to a corporate tax rate, said Cyprys, who keeps an Overweight rating on Blackstone shares.
04/23/19
SBSH
04/23/19
NO CHANGE
SBSH
Citi adds Blackstone to Focus List, removes Chubb and Pioneer Natural
Citi added Blackstone (BX) to its US Focus List on the belief that the shares have more room to run. Blackstone could have "materially more upside," especially considering its "best-in-class" business model and widespread investor appeal, the firm's North America Research team says in a note. It removed Chubb (CB) and Pioneer Natural Resources (PXD) from the US Focus List due to analyst departures.
01/02/19
SUSQ
01/02/19
UPGRADE
Target $31
SUSQ
Positive
Crocs upgraded to Positive at Susquehanna
As reported previously, Susquehanna analyst Sam Poser upgraded Crocs (CROX) to Positive from Neutral. The analyst cited the recent repurchase and conversion of Blackstone's (BX) preferred stock position as it removes a substantial financial overhang from the company's capital structure and shifts more control of the business into the hands of existing and potential shareholders. In addition, the business continues to accelerate as processes and products improve and the brand gains traction, said Poser, who raised his price target to $31 from $25 on Crocs shares.
04/15/19
SBSH
04/15/19
UPGRADE
Target $35
SBSH
Neutral
Citi upgrades Franklin Resources, Artisan to Neutral from Sell
Citi analyst William Katz upgraded both Franklin Resources (BEN) and Artisan Partners (APAM) to Neutral from Sell. The analyst raised his price target to $35 from $28 for the former and to $25 from $20 for the latter. Ahead of the Q1 earnings season, however, the analyst favors the Alternatives. His top picks are Och-Ziff Capital (OZM), Brookfield (BAM) and Blackstone (BX). Katz, though, is "tactically less negative" on the Traditional asset managers.
DHI D.R. Horton
$45.66

-0.76 (-1.64%)

04/22/19
04/22/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Tesla (TSLA) downgraded to Underperform from In Line at Evercore ISI with analyst Arndt Ellinghorst citing his more cautious view on demand for its vehicles, in particular the recent "severe decline" in demand for the Model S and Model X. 2. Schlumberger (SLB) downgraded to Sell from Hold at Tudor Pickering. 3. Dunkin' Brands (DNKN) downgraded to Hold from Buy at Maxim. 4. D.R. Horton (DHI) downgraded to Market Perform from Outperform at Keefe Bruyette with analyst Jade Rahmani citing valuation. 5. Occidental Petroleum (OXY) downgraded to Neutral from Buy at Mizuho with analyst Paul Sankey saying reports of Occidental bidding for Anadarko (APC) are "well outside" his "prior understanding of company strategy." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/22/19
KBWI
04/22/19
DOWNGRADE
Target $47
KBWI
Market Perform
D.R. Horton downgraded to Market Perform from Outperform at Keefe Bruyette
Keefe Bruyette analyst Jade Rahmani downgraded D.R. Horton to Market Perform from Outperform with an unchanged price target of $47. The analyst cites valuation for the downgrade with the shares nearing her price target.
04/17/19
SUSQ
04/17/19
DOWNGRADE
SUSQ
Neutral
Susquehanna downgrades D.R. Horton, Lennar, TRI Pointe in homebuilder shuffle
As previously reported, Susquehanna analyst Jack Micenko downgraded homebuilders D.R. Horton (DHI), Lennar (LEN) and TRI Pointe (TPH), all to Neutral from Positive, stating that he is "taking money off the table" after a period of solid performance from the group and not making a call into the quarter. After visiting 200+ communities, he thinks 2019 has "evolved into a classic spring season for both demand and the stocks," noting that homebuilders' spring trade is typically characterized by a period of underperformance. He lowered his price target on D.R. Horton shares to $46 from $49, cut his target on Lennar to $57 from $64 and lowered his target on TRI Pointe to $14 from $16.
04/17/19
SUSQ
04/17/19
DOWNGRADE
SUSQ
Neutral
D.R. Horton downgraded to Neutral from Positive at Susquehanna
SIRI Sirius XM
$6.11

0.07 (1.16%)

03/15/19
MSCO
03/15/19
INITIATION
Target $6.5
MSCO
Equal Weight
Sirius XM resumed with an Equal Weight at Morgan Stanley
Morgan Stanley analyst Benjamin Swinburne resumed coverage of Sirius XM (SIRI) with an Equal Weight rating and $6.50 price target, noting that acquiring Pandora with shares was dilutive to free cash flow per share but something he considers "a relatively low risk bet." He expects pro forma SiriusXM to grow revenue and adjusted EBITDA at a 6% and 9% 5-year CAGR respectively from 2019-2023. Swinburne also resumed coverage of Liberty Sirius XM (LSXMK) with an Overweight rating.
01/30/19
01/30/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. United Continental (UAL) initiated with a Buy at Argus. 2. Amicus (FOLD) initiated with an Overweight at Cantor Fitzgerald. 3. Take-Two (TTWO) and Zynga (ZNGA) were initiated with a Buy at Goldman Sachs, while Electronic Arts (EA) and Activision Blizzard (ATVI) were initiated with a Neutral. 4. Sirius XM (SIRI) resumed with a Buy at B. Riley. 5. National Grid (NGG) initiated with an Overweight at Barclays. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/29/19
RILY
01/29/19
INITIATION
Target $8
RILY
Buy
Sirius XM resumed with a Buy at B. Riley
B. Riley resumed Sirius XM with a Buy rating and a price target of $8.
01/28/19
01/28/19
UPGRADE
Target $7.25

Buy
Sirius XM upgraded to Buy on Pandora approval boost at Buckingham
As previously reported, Buckingham upgraded Sirius XM (SIRI) to Buy from Neutral and maintained a $7.25 price target. Analyst Matthew Harrigan expects a favorable Pandora (P) shareholder vote tomorrow to approve Sirius' acquisition and management to reiterate transaction benefits on the Q4 conference call on Wednesday. Harrigan said spectrum ownership and Pandora synergies increases Sirius' 2019 upside potential to $9.25
BOX Box
$19.71

0.86 (4.56%)

04/05/19
WELS
04/05/19
NO CHANGE
Target $27
WELS
Outperform
Wells Fargo 'cautiously optimistic' on Box after meetings with CEO
Wells Fargo analyst Philip Winslow said he came away from investor meetings he hosted with Box CEO Aaron Levie "cautiously optimistic" on Box's ability to improve execution on the company's go-to-market strategy and the potential benefits of its product portfolio changes and additions. Winslow, who thinks "reaccelerating growth is still on the table - just not in the timeframe originally forecasted," keeps an Outperform rating and $27 price target on Box shares.
02/28/19
DADA
02/28/19
NO CHANGE
Target $25
DADA
Buy
Box price target lowered to $25 from $30 at DA Davidson
DA Davidson analyst Rishi Jaluria lowered his price target on Box to $25 after its "rough" Q4 results, stating that its billings came in well below consensus. The analyst also notes that the disappointing results and guidance were driven by weakness in EMEA, longer sales cycles pressuring 7-figure deals, and a reduction of spending by one of the company's big customers. Jaluria keeps his Buy rating on Box however, stating that based on the "disappointing quarter, reset to numbers, and potentially growing investor unrest", the company may emerge as a potential private equity takeout target.
02/28/19
RSBL
02/28/19
DOWNGRADE
Target $21
RSBL
Neutral
Rosenblatt downgrades Box to Neutral after 'very disappointing quarter'
As previously reported, Rosenblatt analyst Marshall Senk downgraded Box to Neutral from Buy following what he called a "very disappointing quarter," noting that the company missed on all of its top-line metrics. The bottom line is that management failed to meet the expectations they set and his confidence has been diminished, Senk stated. His view is that the company is going to take at least another two, and maybe more, quarters to show improvement, Senk added. He cut his Q1 and FY20 estimates and lowered his price target on Box shares to $21 from $27.
02/28/19
02/28/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Booking Holdings (BKNG) downgraded to Neutral from Overweight at Atlantic Equities and Piper Jaffray, as well as to Perform from Outperform at Oppenheimer. 2. Box (BOX) downgraded to Sector Weight from Overweight at KeyBanc and to Neutral from Buy at Rosenblatt. 3. HP Inc. (HPQ) double downgraded to Underperform from Buy at BofA/Merrill with analyst Wamsi Mohan citing the company's Q1 report last night. 4. PSEG (PEG) downgraded to Hold from Buy at Deutsche Bank. 5. Dollar General (DG) and Big Lots (BIG) were downgraded to Hold from Buy at Deutsche Bank. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

AAPL

Apple

$211.42

4.98 (2.41%)

12:51
08/19/19
08/19
12:51
08/19/19
12:51
Periodicals
Apple Arcade to likely be priced at $4.99/month, 9to5Mac reports »

Apple Arcade,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FSM

Fortuna Silver Mines

$3.67

-0.01 (-0.27%)

12:48
08/19/19
08/19
12:48
08/19/19
12:48
Hot Stocks
Fortuna Silver reports fatal accident at San Jose mine »

Fortuna Silver Mines said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SVRA

Savara

$2.23

0.03 (1.36%)

12:40
08/19/19
08/19
12:40
08/19/19
12:40
Conference/Events
Savara management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

G

Genpact

$41.30

0.51 (1.25%)

, FB

Facebook

$186.67

3.25 (1.77%)

12:40
08/19/19
08/19
12:40
08/19/19
12:40
Periodicals
Facebook contractor raises wages for Indian content reviewers, Reuters reports »

Genpact (G), a Facebook…

G

Genpact

$41.30

0.51 (1.25%)

FB

Facebook

$186.67

3.25 (1.77%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Sep

  • 24

    Sep

  • 27

    Oct

KAR

KAR Auction

$25.67

0.18 (0.71%)

12:39
08/19/19
08/19
12:39
08/19/19
12:39
Conference/Events
KAR Auction management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 11

    Sep

  • 23

    Sep

  • 13

    Nov

ZS

Zscaler

$74.34

-6.5 (-8.04%)

12:37
08/19/19
08/19
12:37
08/19/19
12:37
Recommendations
Zscaler analyst commentary  »

Zscaler slides after OTR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

  • 10

    Oct

  • 15

    Oct

ENVA

Enova International

$24.92

0.31 (1.26%)

12:37
08/19/19
08/19
12:37
08/19/19
12:37
Conference/Events
Enova International management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 22

    Aug

  • 20

    Sep

  • 13

    Nov

AZN

AstraZeneca

$44.38

0.02 (0.05%)

12:33
08/19/19
08/19
12:33
08/19/19
12:33
Conference/Events
AstraZeneca management to meet with Jefferies »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 09

    Sep

  • 16

    Sep

  • 25

    Sep

  • 02

    Oct

PCG

PG&E

$10.35

-3.95 (-27.62%)

, AMGN

Amgen

$202.49

-1.46 (-0.72%)

12:22
08/19/19
08/19
12:22
08/19/19
12:22
On The Fly
Fly Intel: Wall Street's top stories at midday »

Stocks have been rising…

PCG

PG&E

$10.35

-3.95 (-27.62%)

AMGN

Amgen

$202.49

-1.46 (-0.72%)

PANW

Palo Alto Networks

$196.50

-2.76 (-1.39%)

WB

Weibo

$41.70

4.65 (12.55%)

DRYS

DryShips

$5.19

1.355 (35.38%)

EL

Estee Lauder

$197.80

18.54 (10.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

  • 19

    Aug

  • 04

    Sep

  • 09

    Sep

  • 10

    Sep

  • 16

    Sep

  • 19

    Sep

  • 10

    Oct

  • 15

    Oct

LOW

Lowe's

$95.37

1.46 (1.55%)

, HD

Home Depot

$206.92

3.28 (1.61%)

12:19
08/19/19
08/19
12:19
08/19/19
12:19
On The Fly
Fly Intel: What to watch in Home Depot, Lowe's earnings reports »

Home improvement…

LOW

Lowe's

$95.37

1.46 (1.55%)

HD

Home Depot

$206.92

3.28 (1.61%)

JCP

J.C. Penney

$0.61

0.0122 (2.04%)

SHLD

Sears

$0.00

(0.00%)

AMZN

Amazon.com

$1,823.13

31.31 (1.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 21

    Aug

  • 23

    Sep

  • 25

    Sep

  • 27

    Oct

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
08/19/19
08/19
12:17
08/19/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,202.00

25.06 (2.13%)

, GOOGL

Alphabet Class A

$1,204.36

25.67 (2.18%)

12:16
08/19/19
08/19
12:16
08/19/19
12:16
Hot Stocks
Trump says 'Google should be sued' over role in 2016 election »

President Donald Trump…

GOOG

Alphabet

$1,202.00

25.06 (2.13%)

GOOGL

Alphabet Class A

$1,204.36

25.67 (2.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 27

    Oct

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
08/19/19
08/19
12:16
08/19/19
12:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APAM

Artisan Partners

$26.64

0.43 (1.64%)

12:14
08/19/19
08/19
12:14
08/19/19
12:14
Conference/Events
Artisan Partners management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

ARMK

Aramark

$40.72

3.65 (9.85%)

, PCG

PG&E

$10.43

-3.87 (-27.06%)

12:13
08/19/19
08/19
12:13
08/19/19
12:13
On The Fly
Aramark upgrades, PG&E double downgrade among today's top analyst calls »

Check out today's top…

ARMK

Aramark

$40.72

3.65 (9.85%)

PCG

PG&E

$10.43

-3.87 (-27.06%)

CVX

Chevron

$117.16

1.37 (1.18%)

XOM

Exxon Mobil

$69.22

0.92 (1.35%)

BTU

Peabody Energy

$19.31

0.13 (0.68%)

ARLP

Alliance Resource Partners

$14.95

(0.00%)

SONO

Sonos

$13.14

1.24 (10.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

QUOT

Quotient Technology

$7.84

0.035 (0.45%)

12:11
08/19/19
08/19
12:11
08/19/19
12:11
Hot Stocks
Elk Creek Partners reports 5.37% passive stake in Quotient Technology »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 12

    Sep

12:05
08/19/19
08/19
12:05
08/19/19
12:05
General news
Treasury's $87 B 3- and 6-month bill auctions were mixed »

Treasury's $87 B 3-…

BMA

Banco Macro

$34.53

-3.75 (-9.80%)

12:00
08/19/19
08/19
12:00
08/19/19
12:00
Hot Stocks
Banco Macro falls -9.8% »

Banco Macro is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBAR

BBVA

$5.29

-0.575 (-9.80%)

12:00
08/19/19
08/19
12:00
08/19/19
12:00
Hot Stocks
BBVA falls -10.0% »

BBVA is down -10.0%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCG

PG&E

$10.29

-4.01 (-28.04%)

12:00
08/19/19
08/19
12:00
08/19/19
12:00
Hot Stocks
PG&E falls -27.9% »

PG&E is down -27.9%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EL

Estee Lauder

$197.12

17.86 (9.96%)

12:00
08/19/19
08/19
12:00
08/19/19
12:00
Hot Stocks
Estee Lauder rises 9.9% »

Estee Lauder is up 9.9%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

MYOV

Myovant Sciences

$7.90

0.92 (13.18%)

12:00
08/19/19
08/19
12:00
08/19/19
12:00
Hot Stocks
Myovant Sciences rises 13.1% »

Myovant Sciences is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NM

Navios Maritime

$4.98

0.58 (13.18%)

12:00
08/19/19
08/19
12:00
08/19/19
12:00
Hot Stocks
Navios Maritime rises 13.3% »

Navios Maritime is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REPYY

Repsol

$0.00

(0.00%)

11:56
08/19/19
08/19
11:56
08/19/19
11:56
Downgrade
Repsol rating change at Barclays »

Repsol downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLM

Martin Marietta

$254.47

-0.27 (-0.11%)

11:56
08/19/19
08/19
11:56
08/19/19
11:56
Conference/Events
Martin Marietta management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

  • 20

    Aug

  • 21

    Aug

  • 13

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.